Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bio-Rad, Myriad RBM To Commercialize Biomarker Kits | Contract Pharma

What are you searching for?

Sign in
Breaking News

Bio-Rad, Myriad RBM To Commercialize Biomarker Kits

New assays expand Bio-Rad’s current suite

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bio‑Rad Laboratories and Myriad RBM, a wholly owned subsidiary of Myriad Genetics, have partnered to develop and distribute high-quality immunoassay kits. Myriad RBM has granted Bio-Rad exclusive distribution rights, for research purposes, to its catalog of quantitative multiplexed immunoassays currently available to run on Bio-Plex 200, Bio-Plex 3D, and Bio-Plex MAGPIX instruments.
 
Myriad RBM’s assays address needs for multiplex testing of samples with very low volumes when studying toxicology, oncology, immunology, and cardiovascular and other diseases. The new assays expand Bio-Rad’s current suite of assays.
 
“Together we are able to provide hundreds of new biomarkers for both human and non-human panels to our Bio-Plex multiplex immunoassay system menu,” said Brad Crutchfield, Bio-Rad vice president and group manager, Life Science Group. “Moving forward, Myriad RBM and Bio‑Rad will collaborate to design new products to meet the evolving requirements of our customers.”
 
“This agreement combines Myriad RBM’s industry-leading menu of multiplexed immunoassays with Bio‑Rad’s unrivaled global commercial distribution capabilities,” said Craig Benson, president of Myriad RBM. “Our partnership with Bio‑Rad will help researchers and clinicians on the front lines of medicine to develop biomarker profiles that may predict, detect, or monitor disease progression in an effort to optimize treatment and improve patient care.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics